fbpx

Insoo Park, CEO, Ecosense, Discusses Radon – The Leading Cause of Non-Smoker Lung Cancer

DocWire News recently spoke with Insoo Park, Founder and CEO of Ecosense, Inc. Mr. Park's discussion focused on radon, the number one cause of non-smoker lung cancer. Mr. Park’s goal is to empower consumers to...
Advertisement

Journal Reading List

Multiple Myeloma Knowledge Hub

Long-Term Follow-up From GRIFFIN Confirms Durability of Daratumumab Responses in Transplant-Eligible Myeloma

According to extended follow-up from the GRIFFIN trial, the combination of daratumumab and lenalidomide, bortezomib, and dexamethasone (D-RVd) continued to provide deep and durable...

Understanding the Mechanisms of CAR T-Cell Toxicities for Their Prevention and Management

Despite the successes of chimeric antigen receptor (CAR) T-cell therapy against hematologic malignancies, toxicities continue to limit the therapy’s potential. Cytokine release syndrome (CRS)...
CAR T-cell

Approaches to Expand CAR T-Cell Therapy to Solid Tumors

Chimeric antigen receptor (CAR) T-cell therapy has been very effective against a growing number of hematologic malignancies, including diffuse large B-cell lymphoma, B-cell acute...

Survey Defines COVID’s Impact on Delivery of CAR T-Cell Therapy in Europe

A recent letter to Bone Marrow Transplantation describes results of a survey that aimed to capture the impact of the COVID-19 pandemic’s first wave,...
close up patient man hand with label and drip (IV saline tube) waiting for operation of chemotherapy medical , healthcare and cancer day concept

Infectious complications of CAR T-cell therapy: a clinical update

An article appearing in the journal Therapeutic Advances in Infectious Disease called for research to explore the infectious complications of chimeric antigen receptor (CAR)...

Applying CAR T-Cell Therapy to Fight Malignant Mesothelioma

Malignant mesothelioma is a treatment-resistant type of cancer that starts in the mesothelial lining of the pleura or the abdominal cavity. Patients with this...

Research Seeks Other CAR T-Cell Targets in Multiple Myeloma

Chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment of multiple myeloma, but the disease is still incurable, and many patients experience relapse or...
Nurse and patient

Research Explores CAR T-Cell Therapy to Treat Autoimmune Diseases, Viral Infections, and More

A recent article in the journal Biomedicines reviewed the potential of chimeric antigen receptor (CAR) T-cell therapy in disease states beyond cancer. The article,...
Advertisement
Advertisement